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Although some urogenital drugs such as 
tamsulosin or tolterodine have reached 
blockbuster status, the pharmacotherapy 
of urogenital disorders has been lagging 
behind many other therapeutic areas for 
a long time. Malformations and trauma 
of the urogenital tract are a clear domain 
of surgery, and malignant urogenital dis-
ease has more in common with malig-
nancies of other tissues than with other 
urogenital disorders; hence, both groups 
of disorders are not topical for this jour-
nal. However, a large number of func-
tional disorders of the urogenital tract 
exist. These include lower urinary tract 
symptoms suggestive of benign prostatic 
hyperplasia (LUTS/BPH), the overactive 
bladder symptom complex (OAB), stress 
urinary incontinence, erectile dysfunc-
tion (ED), ejaculation disorders, preterm 
labor, and ureteral stone disease. Many 
of these conditions are highly preva-
lent in the general population. Despite 
being largely functional disorders, their 
treatment often was based on surgical 
approach (e.g., LUTS/BPH) or limited 
to conservative management.
InsuffIcIent pathophysIologIcal 
understandIng
The physiology and pathophysiology 
of the urogenital system is more com-
plex than often assumed. For example, 
α1-adrenoceptor antagonists for the 
treatment of LUTS/BPH have long been 
assumed to primarily work by relaxing 
prostate smooth muscle, but meanwhile 
it has become clear that this mechanism 
at best can explain part of their therapeu-
tic effects (Michel, 2010). Similarly, mus-
carinic receptor antagonists have long been 
thought to act by relaxing bladder detru-
sor smooth muscle, but we now realize that 
effects on urothelial mediator release and/
or afferent nerves may also contribute to 
their therapeutic effects (Yamaguchi, 2010). 
Moreover, the function of urogenital tissues 
is often controlled by the central nervous 
system (Birder et al., 2010) but this is less 
well understood than peripheral control, 
particularly at the smooth muscle level. A 
better understanding of the physiology and 
pathophysiology of the urogenital system is 
urgently needed to provide the basis for a 
more effective and/or better tolerated phar-
macotherapy of related disorders.
strong placebo effects
The last two decades have witnessed 
extra-ordinary progress in the treatment 
of many functional urogenital disorders. 
The primary treatment of LUTS/BPH has 
largely shifted from surgical to medical 
treatments, the medical treatment of OAB 
has experienced major progress in toler-
ability, and effective oral treatment of ED 
became available. Nevertheless, many ther-
apeutic challenges remain, e.g., the use of 
α1-adrenoceptor antagonists for the treat-
ment of LUTS/BPH (Milani and Djavan, 
2005) or that of muscarinic receptor antag-
onists for the treatment of OAB (Chapple 
et al., 2008) has only limited efficacy rela-
tive to placebo. Actually, the relative efficacy 
of placebo treatment in some urogenital 
disorders is surprisingly high but not well 
understood.
rIsk–benefIt ratIos In vulnerable 
target populatIons
Fortunately, many urogenital disorders 
cause limited secondary morbidity or 
even mortality. Nevertheless, they often 
cause major adverse effects on quality of 
life, interestingly in several cases not only 
for the afflicted patient but also for their 
partners. Many urogenital disorders affect 
largely elderly patients who are character-
ized by frequent comorbidities and comed-
ications. These can cause disease-associated 
vulnerabilities but also risks due to drug–
drug interactions. While preterm labor 
affects a much younger patient group, the 
vulnerability of the unborn child also raises 
specific safety concerns. Thus, the combina-
tion of non-life-threatening diseases on the 
one hand and of highly   vulnerable patient 
populations on the other hand,   creates 
a need for particularly safe drugs. How 
this risk–benefit ratio should be defined 
remains under discussion as highlighted 
by the fact that drugs such as duloxetine 
for the treatment of stress urinary incon-
tinence (Michel and Oelke, 2005) and 
dapoxetine for the treatment of premature 
ejaculation (McCarty and Dinsmore, 2010) 
were registered by European but not US 
authorities.
local accessIbIlIty
Several urogenital tissues are in princi-
ple accessible to local, i.e., trans-urethral 
treatments as exemplified by the use of 
botulinum A toxin (Karsenty et al., 2008). 
Alternatively, drugs which are excreted in 
active form via the kidneys may also yield 
higher exposure in urogenital tissues than 
systemically. However, such pharmacoki-
netic peculiarities of the urogenital tract 
have only been insufficiently explored.
conclusIon
All of the above factors create challenges 
for the future pharmacotherapy of uro-
genital disorders, and it is hoped that this 
journal will contribute to meeting those 
challenges.
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